Feb 18, 2021
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis
Feb 11, 2021
Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin)
Dec 15, 2020
Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis
Jun 18, 2020
Almirall Announces FDA Approval Of Updated Label For Seysara® (Sarecycline) Tablets
Jun 11, 2020
Almirall Enters the IBEX 35
Jan 09, 2020
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
Jan 09, 2020
Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology
Jan 09, 2020
Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine
Oct 15, 2019
Global Vaginal Laxity Market Size, Trends & Forecasts Report 2019-2023 Featuring Almirall, Fotona, Hologic, Viveve Medical
Jul 25, 2019
Almirall Issues Call For Grant Submissions For Development of New Immunodermatology Therapies
Jun 17, 2019
Almirall Partners With AARS To Raise Awareness About The Burden Of Disease And Importance Of Education For Dermatology Professionals For National Acne Awareness Month
Apr 11, 2019
Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose
Mar 04, 2019
Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Mar 04, 2019
Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business
Feb 05, 2019
Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
Jan 17, 2019
Novel Oral Antibiotic Treatment Seysara(TM) (sarecycline) Now Available
Nov 13, 2018
Actinic Keratosis: Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Oct 23, 2018
Actinic Keratosis Treatment Market Would Reach US$ 8 Bn, With a CAGR of 7.1%, By 2028 - Future Market Insights
Oct 19, 2018
Almirall LLC Launches New Name at Fall Clinical Dermatology Congress
Sep 21, 2018
Almirall acquires Allergan U.S. medical dermatology portfolio*